Ruth Wexler, PhD
Ruth Wexler, PhD, is a highly respected Pharmaceutical Executive with more than 30 years of experience in drug discovery. During her career, she successfully built and led high-achieving discovery teams spanning cardiovascular/metabolic diseases, fibrosis, and immunology that advanced 38 drug candidates into development, which included two important approved drugs, the antihypertensive agent losartan and the anticoagulant apixaban.
Dr. Wexler has held executive leadership positions at both Bristol Myers Squibb (BMS) and DuPont Pharmaceuticals. At BMS she rose to the level of Vice President, Cardiovascular, Immunology and Fibrosis Discovery Chemistry in 2018. She has served as a Core Member on Strategy and Licensing teams and sat on multiple Joint Research Committees in alliances with academia, and with other pharma and biotech companies. In August 2021, Ruth retired from BMS, and formed R. Wexler Consulting, LLC and currently serves as a pharmaceutical R&D executive advisor and drug discovery consultant.
Dr. Wexler received her PhD in Organic Chemistry from the University of Pennsylvania and earned a BA in Chemistry from Boston University.